![](https://investorshub.advfn.com/uicon/113775.png?cb=1640546002)
Saturday, September 27, 2014 9:32:48 PM
Odds are that TKM-ebola will come out on top, but, the reality is that there isn't enough data yet to know which therapy will be best overall. That won't happen until each of the companies with experimental therapies treats 100 to 200 sick patients.
For more info on companies doing work in the ebola space you may want to read the following:
Tekmira Pharmaceuticals Is More Than Just A Short-Term Ebola Trade
http://seekingalpha.com/article/2455065-tekmira-pharmaceuticals-is-more-than-just-a-short-term-ebola-trade
For the ones most likely to be used you can read this one:
4 Companies To Look At After WHO Ebola Consultation In Geneva
http://seekingalpha.com/article/2478565-4-companies-to-look-at-after-who-ebola-consultation-in-geneva
'JDUser1963'
ROFLMAO, there are no other companies. Only TMKR. They want the World to think the scientists are all hot on the ebola tail, the truth is it takes a long time to go from lab to patient as in years. Mapp has already shown it can have a serious allergic side effect, and that's about it folks! Nothing to deliver to Africa right now. So what to produce? Who will produce it? Who has the process design for high output? Who has the infrastructure supply management chain? Who has the experience with animal models and now quasi clinical field use? Who has the quickest patent recovery results?
TKMR. No argument, this is as slam dunk as it gets. We should be talking about military containment and medical treatment sites at this point and who bears the cost because I can guarantee its already a done deal. The new hedge fund moves were the tip off, they always have the IN.
Recent ABUS News
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/18/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:16:15 PM
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels • GlobeNewswire Inc. • 06/06/2024 03:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:00:21 AM
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Arbutus to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:07:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:18 AM
- Arbutus to Present Imdusiran Data at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 01:03:23 PM
- Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value • Business Wire • 05/17/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/09/2024 12:00:20 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM